Evidence map›Paper›PMID 38533726›Full record

ArticleThe Analyst2024

Conformational fingerprinting with Raman spectroscopy reveals protein structure as a translational biomarker of muscle pathology.

James J P Alix, Maria Plesia, Alexander P Dudgeon, Catherine A Kendall, Channa Hewamadduma, Marios Hadjivassiliou, Gráinne S Gorman, Robert W Taylor, Christopher J McDermott, Pamela J Shaw and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Analyst, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

James J P AlixSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.ORCID http://orcid.org/0000-0001-8391-9749
Maria PlesiaSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
Alexander P DudgeonBiophotonics Research Unit, Gloucestershire Hospitals NHS Foundation Trust, UK.ORCID http://orcid.org/0000-0002-4536-1147
Catherine A KendallBiophotonics Research Unit, Gloucestershire Hospitals NHS Foundation Trust, UK.
Channa HewamaddumaNational Institute for Health and Care Research Sheffield Biomedical Research Centre, Sheffield, UK.
Marios HadjivassiliouNational Institute for Health and Care Research Sheffield Biomedical Research Centre, Sheffield, UK.
Gráinne S GormanWellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Robert W TaylorWellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Christopher J McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
Pamela J ShawSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
Richard J MeadSheffield Institute for Translational Neuroscience, University of Sheffield, UK. j.alix@sheffield.ac.uk.
John C DayInterface Analysis Centre, School of Physics, University of Bristol, UK.
University of Sheffield · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRoyal Hallamshire Hospital · GBGloucestershire Hospitals NHS Foundation Trust · GBUniversity of Bristol · GBUniversity of Exeter · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Neuromuscular disorders are a group of conditions that can result in weakness of skeletal muscles. Examples include fatal diseases such as amyotrophic lateral sclerosis and conditions associated with high morbidity such as myopathies (muscle diseases). Many of these disorders are known to have abnormal protein folding and protein aggregates. Thus, easy to apply methods for the detection of such changes may prove useful diagnostic biomarkers. Raman spectroscopy has shown early promise in the detection of muscle pathology in neuromuscular disorders and is well suited to characterising the conformational profiles relating to protein secondary structure. In this work, we assess if Raman spectroscopy can detect differences in protein structure in muscle in the setting of neuromuscular disease. We utilise

Indexed as

BiomarkersMuscular Dystrophy, DuchenneSpectrum Analysis, RamanAmyotrophic Lateral SclerosisAnimalsHumansMaleMiceMuscle, SkeletalBiomarkers

Identifiers

PMID38533726
PMCPMC11056770
OpenAlexW4393226371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.